Form 4: Guardant Health Director Sells Shares Under 10b5-1 Plan

Guardant Health Director Ian T. Clark sold 6,876 shares of common stock for approximately $106.90 per share in a pre-planned transaction.

Summary

• Ian T. Clark, a Director of Guardant Health, Inc. (GH), sold 6,876 shares of common stock.
• The transaction occurred on May 20, 2026, at a weighted average price of $106.9006 per share.
• The shares were sold in multiple transactions at prices ranging from $106.85 to $106.99 per share.
• The sale was conducted pursuant to a Rule 10b5-1(c) pre-planned trading arrangement.
• Following the transaction, Mr. Clark indirectly beneficially owns 2,975 shares through The Thornton-Clark Family Trust.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While an insider sale can sometimes be perceived negatively, the disclosure that it was executed under a Rule 10b5-1 plan mitigates concerns that it's based on new, adverse material information.

Positives

• The transaction was executed under a Rule 10b5-1(c) plan, indicating a pre-scheduled sale rather than a reaction to new, non-public information.

Negatives

• A director selling shares can sometimes be perceived negatively by the market, as it reduces their direct stake in the company.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance.

Industry Context

StockSavvy.ai notes that insider sales, even when pre-planned under Rule 10b5-1, are routinely monitored by investors for insights into management's confidence. For Guardant Health, a company in the precision oncology and diagnostics sector, such transactions are typically viewed in the context of broader market conditions and individual financial planning rather than as a direct signal of company-specific operational changes, especially given the pre-arranged nature.

Comparison to Industry Standards

• Not applicable as this filing details an individual insider transaction rather than company performance metrics that can be benchmarked against industry standards or competitors.

Related Party Transactions

• Ian T. Clark indirectly beneficially owns 2,975 shares through The Thornton-Clark Family Trust, where J Thornton-Clark & I Clark are trustees.

Stakeholder Impact

• Shareholders: The sale by a director could lead to minor short-term market speculation, but the 10b5-1 plan suggests it is not a signal of fundamental change. The reduction in direct insider ownership is minimal relative to the company's overall market capitalization.

Key Dates

Recommendation

The insider sale by Director Ian T. Clark, executed under a Rule 10b5-1 plan, is a routine event for personal financial management and does not indicate a change in the company's fundamentals or future prospects. It provides no new information to warrant a change in investment thesis, thus a 'hold' recommendation is appropriate.

Keywords

Guardant Health, GH, Insider Sale, Form 4, Director, Stock Transaction, 10b5-1 Plan, Ian T. Clark